+44 (0)203 011 5574 info@orthocg.com
Spineology Inc. Announces New Board Members

Spineology Inc. Announces New Board Members

ST. PAUL, Minn.–(BUSINESS WIRE)–Spineology Inc., the innovator in anatomy-conserving spine surgery, announced today the appointment of two new members to its Board of Directors, Bob Paulson and Phil Soran.

Mr. Soran is a successful serial entrepreneur who has founded several technology companies and was inducted into the Minnesota Business Hall of Fame in 2016. He was co-founder, President, and CEO of XIOtech Corp., which sold to Seagate Technology for $360 million in 2000. Later, he served as President and CEO of Compellent Technologies, which went public in 2007 and was subsequently acquired by Dell Inc. for $960 million. Most recently, he co-founded Flipgrid, an educational technology company, which was purchased by Microsoft in June. He currently serves on the boards of Piper Jaffray, SPS Commerce, and Foodsby.

“Spineology is an exciting company with a great market opportunity. I look forward to finding ways to add value to this strong team,” commented Mr. Soran.

Mr. Paulson has a long history of leadership in the medical device arena, having most recently served as President and CEO of NxThera, Inc., a company focused on treating prostate conditions, leading and evolving the company from concept to commercialization, culminating with the acquisition of NxThera by Boston Scientific earlier this year for up to $406 million. Prior to NxThera, Mr. Paulson was President and CEO of Restore Medical, an innovator in the treatment of snoring and sleep apnea, leading the company through a successful Initial Public Offering (IPO) and subsequent sale to Medtronic Inc. He currently serves as a board member for Veran Medical Technologies and Sun BioPharma.

“I am delighted to have the opportunity to join the Spineology board as the company continues to expand the adoption and utilization of its pioneering, anatomy-conserving technology to improve the lives of patients suffering from degenerative spinal conditions,” said Mr. Paulson.

“Bob and Phil are both accomplished business leaders and experienced board members, and we feel fortunate to have them join our Board of Directors,” said John Booth, Spineology’s Chief Executive Officer. “We think they’ll add great value to the board and we look forward to leveraging their unique skill sets as we continue to scale the business.”

About Spineology Inc.
Spineology Inc. provides innovative, anatomy-conserving spinal technologies for surgeons and their patients. Spineology surgical techniques conserve spinal bone, ligament and muscle tissue. Spineology is committed to increasing procedural efficiency, reducing surgical morbidity and accelerating patient recovery. Learn more at spineology.com.

Contacts
Spineology Inc.
John Booth, 651-256-8511
jbooth@spineology.com
or
Risdall
Dave Folkens, 651-286-6713
dave@risdall.com

SOURCE: BusinessWire – https://www.businesswire.com/news/home/20181204005141/en/Spineology-Announces-New-Board-Members

With 13 years of marketing and eCommerce experience, he brings a wealth of digital knowledge and expertise to the business.

Tom joined in 2018, leading the launch of Ortho Consulting Groups brand, marketing strategy, conference planning and the ongoing development of the Ortho Consulting Groups websites and CRM.

WishBone Medical, Inc. acquires Response Ortho

WishBone Medical, Inc. acquires Response Ortho

Warsaw, Indiana, November 28, 2018 – WishBone Medical, Inc. announces the acquisition of Response Ortho. Response Ortho has a complete pediatric line of external and internal fixation and deformity correction products.

Response Ortho has been in business for fourteen years and has built a modern, high-tech manufacturing facility with access to an experienced engineering and technical labor force. Because of this, product development and launch activities have been dramatically accelerated for WishBone Medical with the Response Ortho offering of over thirty developed pediatric orthopedic systems, with multiple patents, including the award winning “Smart Correction” Hexapod Fixator and “Click2Correct” surgical preoperative planning software. Eighteen of the current product systems can be sold in the US now and we are working on FDA clearance for the remaining products. Our commitment is to provide global access to anatomically appropriate innovative implants and instruments in sterile packed, single use, disposable kits for children.

Nick Deeter, Chairman of the Board and CEO at WishBone Medical, said, “With the acquisition of Response Ortho, we are thrilled about our pediatric orthopedic product offerings. The combination of Response Ortho’s thirty product systems and WishBone’s eight product systems will give WishBone Medical the broadest product portfolio in pediatric orthopedics worldwide.” Mr. Deeter added, “These pediatric orthopedic products can be delivered in sterile packed, procedural kits anywhere in the world, next day, to the surgeons that care for children.”

Sehmuz Isin, CEO of Response Ortho said, “We are excited that Response Ortho is now part of WishBone Medical. Our primary focus has been outside the US, and we will now be able to offer these innovative orthopedic product systems everywhere. Having more than 50 years of combined experience, Nick and I understand the unmet needs and will provide global solutions to children with orthopedic issues.”

About WishBone Medical, Inc.

WishBone Medical is a Global pediatric orthopedic company, committed to providing anatomically appropriate innovative implants and instruments in sterile packed, single use, disposable kits, to prevent infection, reduce overall costs for our customers and achieve the best outcomes for children around the world who are still growing.

About Response Ortho

Response Ortho is a vertically integrated, ISO 13485 certified, CE Mark lean company that is focused on the orthopedic industry with modern equipment and scalable technology. Response Ortho is located in Istanbul, Turkey.

For further information, visit www.WishBoneMedical.com or call Andrew Miclot, Vice-Chairman and President at 574-306-4006.

SOURCE: Wishbone Medical, Nov 28, 2018 – https://www.wishbonemedical.com/news/2018/11/28/wishbone-medical-inc-acquires-response-ortho

With 13 years of marketing and eCommerce experience, he brings a wealth of digital knowledge and expertise to the business.

Tom joined in 2018, leading the launch of Ortho Consulting Groups brand, marketing strategy, conference planning and the ongoing development of the Ortho Consulting Groups websites and CRM.

FDA Commissioner Scott Gottlieb, M.D. and Jeff Shuren, M.D., Director of the Center for Devices and Radiological Health, on new steps to modernize FDA’s 510(k) program

FDA Commissioner Scott Gottlieb, M.D. and Jeff Shuren, M.D., Director of the Center for Devices and Radiological Health, on new steps to modernize FDA’s 510(k) program

Forty-two years ago, Congress passed the law establishing the framework for evaluating the safety and effectiveness of medical devices. Today, we’re announcing changes to modernize the FDA’s 510(k) clearance pathway, which accounts for the majority of devices that the FDA reviews. We’re pursuing these changes to help keep pace with the increasing complexity of rapidly evolving technology. The new technology that we’re seeing holds tremendous public health promise for patients. But with the advances also come new complexities that can make the review of safety and effectiveness more challenging. The framework we propose is aimed at efficiently advancing beneficial technology to patients, while solidifying FDA’s gold standard for safety.

We believe that where appropriate, new medical devices that come to market under the 510(k) pathway should either account for advances in technology or demonstrate that they meet more modern safety and performance criteria. We want to make sure that new devices are evaluated against advances in technology that can improve patient safety and performance. In making these reviews, where appropriate, we want to rely on modern safety and performance criteria. At the same time, we’re going to pursue additional actions that will allow the FDA to retire outdated predicates, especially in cases where we’ve seen safer or more effective technology emerge.

We believe firmly in the merits of the 510(k) process. But we also believe that framework needs to be modernized to reflect advances in technology, safety and the capabilities of a new generation of medical devices. In short, we believe that it’s time to fundamentally modernize an approach first adopted in 1976, when Congress considered the vast diversity of devices that would become subject to the FDA’s regulatory oversight and established many of the predicate devices that served as the basis for 510(k) clearances during the last 40 years.

The 510(k) process allows the FDA to recognize that medical devices exist across a continuum of complexity and risk and that the scope of premarket review should reflect this risk continuum. This is a contemporary approach to regulation. A one-size-fits-all regulatory approach wouldn’t optimize public health outcomes, wouldn’t be efficient in advancing beneficial new technologies to patients, and wouldn’t allow the FDA to effectively prioritize its scientific resources.

Congress’s creation of the 510(k) process was a paradigm shift from the FDA’s regulation of drugs. It recognized the distinct challenges of regulating such a broad, diverse group of medical products. Today, the FDA regulates more than 190,000 distinct devices. Although the regulatory approach to devices is different than for drugs, the public health objective – assuring that all medical products meet the FDA’s standards for safety and effectiveness – is the same.

The 510(k) pathway represents a more contemporary approach to the risk-based regulation of medical products, but this doesn’t mean the pathway is perfect or not in need of change.

The staff of the FDA’s Center for Devices and Radiological Health (CDRH) has leveraged this risk-based paradigm to develop innovative and forward-leaning regulatory policy that meets our gold standard for safety and effectiveness. In recent months, we’ve taken many new steps to advance these goals. Many of these efforts aim at adopting a more modern process that allows the FDA to more readily incorporate new technologies that improve the safety and performance of medical devices into new predicates to serve as benchmarks for future clearances.

Some of the recent innovative policies include efforts to promote the use of real world evidence in regulatory decision-making; to modernize the De-Novo pathway for low to moderate risk novel devices; to enable the use of rigorous, consensus objective criteria to serve as a predicate for future clearances; to build a national patient safety net; to re-envision a regulatory paradigm for digital health products and in vitro diagnostics; and to chart a premarket review path for breakthrough products. At the same time, we’ve also advanced pathways that can help enable timely patient access to new, innovative and potentially transformative medical devices to help safely treat devastating diseases. For instance, we’ve promoted new ways to safely advance medical devices to diagnose cancer, repair damaged hearts and manage diabetes.

Advances in material science, digital health, 3D printing and other technologies continue to drive an unparalleled period of invention in medical devices. It’s vital that the FDA’s regulatory approach continue to evolve and modernize to safely and efficiently advance these opportunities. Not only must we keep pace with this complexity and innovation, but we must also stay ahead of the new and evolving risks that sometimes accompany this progress.

That’s why, this past April, FDA issued its Medical Device Safety Action Plan: Protecting Patients, Promoting Public Health. We recognized that there were opportunities for us to continue to enhance our programs to help improve device safety. Our policy ideas spanned the life cycle for devices, including ways to drive innovation of safer devices premarket, and enhance post market patient safety. We’ve made significant progress to advance that plan.

Modernizing the 510(k) Pathway

As part of the Safety Action Plan, we committed to strengthen and modernize the 510(k) program. This is a pathway used for clearance of low- to moderate-risk devices that are substantially equivalent to a device already on the market – otherwise known as a predicate device.

FDA’s 510(k) program is the most commonly used device premarket review pathway. In 2017, CDRH cleared 3,173 devices through the 510(k) pathway, representing 82 percent of the total devices cleared or approved. The 510(k) program has been strengthened and refined in many ways. This has been especially true in recent years, as CDRH made a systematic, concerted effort to improve the program’s performance, predictability, efficiency and safety.

Today, following the close of the public comment period and our review of the feedback on the Safety Action Plan, we’re announcing new steps and proposed actions to substantially build on these efforts. We’re focusing on new policy efforts that we plan to advance to help the 510(k) program keep pace with innovation, promote modern patient care and match our evolving understanding of benefits and risks. Our new plans are aimed at continuing to ensure that new and existing devices meet our gold standard for safety and effectiveness as technology rapidly advances.

The most impactful way that we can promote innovation and improved safety in the 510(k) program is to drive innovators toward reliance on more modern predicate devices or objective performance criteria when they seek to bring new devices to patients.

In the 510(k) pathway, manufacturers generally rely on comparative testing against predicate devices to show that a new device is as safe and effective as the predicate device. Older predicates might not closely reflect the modern technology embedded in new devices, or our more current understanding of device benefits and risks. In some cases, the predicate could be decades old. Data show that nearly 20 percent of current 510(k)s are cleared based on a predicate that’s more than 10 years old. That doesn’t mean the products are unsafe. But it does mean that some devices may not be continually improving, which is the hallmark of health technologies.

We believe that newer devices should be compared to the benefits and risks of more modern technology; that is why we’re looking at ways to promote the use of more recent predicates. To advance these goals, in the next few months CDRH is considering making public on its website those cleared devices that demonstrated substantial equivalence to older predicate devices. We’re considering focusing on predicates that are more than 10 years old as a starting point, so that the public is aware of those technologies. Our goal in focusing on older predicates is to drive sponsors to continually offer patients devices with the latest improvements and advances.

Before proceeding, we’ll seek public feedback on whether we should make public those devices or those manufacturers who make technologies that rely on predicates that are more than 10 years old, whether other criteria should inform our point of reference, and whether there are other actions we should take to promote the use of more modern predicates. To be clear, we don’t believe devices that rely on old predicates are unsafe, or that older devices need to be removed from the market. However, we believe that encouraging product developers to use more modern predicates would give patients and their doctors a choice among older and newer versions of a type of device, promote greater competition to adopt modern features that improve safety and performance, and help make sure that newer devices reflect more modern technology and standards that can improve patient care and outcomes. It would help the overall product environment continue to evolve in the direction toward more modern performance standards.

This market-based approach will promote the right kind of innovation for patients. Innovation that reflects the most modern principles. Among other steps, we’re developing proposals to potentially sunset certain older predicates and promote the use of more modern predicates. We’ll consider whether this approach should become a requirement in the future. To achieve some of these public health goals, we may need to seek additional guidance from Congress.

We’re considering this approach because the devices we review through the 510(k) program are increasingly complex. They often involve different technological features from the predicates on which they’re based. Newer devices are more often interconnected and interoperable, increasing cybersecurity threats. Miniaturization of device components has allowed devices to become smaller and more portable. Devices more frequently use automation and robotics, and advanced materials, changing the way healthcare providers and patients interact with them.

To keep pace with these developments and advance these goals, in early 2019, FDA intends to finalize guidance establishing an alternative 510(k) pathway that allows manufacturers of certain well-understood device types to rely on objective safety and performance criteria to demonstrate substantial equivalence as a way to make it more efficient to adopt modern criteria as the basis for the predicates that are used to support new products. Our goal in finalizing this pathway that we discussed in our Medical Device Safety Action Plan is to expand its use broadly across the 510(k) program and make it the primary pathway for devices eligible for 510(k) review.

We believe this approach is the future of the 510(k) program. Rather than looking to the past as a baseline for safety and effectiveness – and rely on predicate devices that are sometimes decades old as our point of comparison – our premarket review would be based on a contemporary baseline that looks to the future and a baseline that can be updated as technologies advance. Sometimes, by relying on old predicates, it can actually make it more difficult for more advanced technology to reach patients since it’s harder for an innovative product to bridge to an outdated technology reflected in a decades-old predicate. Our new proposed approach enables us to help improve safety and performance, as appropriate, and ensure new products can more easily reflect beneficial new advances.

We’re planning to rename this new approach the “Safety and Performance Based Pathway” to reflect its focus on advancing improved safety and performance of new products. Through this new path, a company would demonstrate that a novel device meets modern performance-based criteria that have been established or recognized by the FDA and reflect current technological principles. These criteria would reflect the safety and performance of modern predicate devices. We’d like this efficient new pathway to eventually supplant the practice of manufacturers comparing their new device technologically to a specific, and sometimes old, predicate device.

This modern framework is a direct and transparent approach to demonstrating the safety and effectiveness of low to moderate risk devices. This alternative pathway to substantial equivalence would provide more direct evidence of the safety and performance of a device and better information for patients and providers to make well-informed health care decisions. In addition, with this new approach, the FDA may drive greater market competition to develop safer devices. Manufacturers would be able to demonstrate that their products meet or exceed objective safety and performance criteria that are based on modern technological principles. And companies could also, for the purposes of supporting coverage decisions, more readily demonstrate to payors that their products perform better than other devices on the market.

Promoting Greater Transparency and Post-Market Surveillance

We’re proposing these changes after accounting for all of the improvements to our 510(k) review in recent years. Today, we are posting a performance report that highlights some of the key achievements of the past decade, including the measures taken to increase the predictability and transparency of the 510(k) review process. These efforts include the more than 50 final guidance documents on important medical device policy issues that we’ve issued since 2009.

Importantly, we’ve increased expectations for the quality and quantity of information required in 510(k) submissions, resulting in a more than doubling of the size of submissions – now, an average of 1,185 pages, compared to 475 pages in 2009. And while our reviewers have spent more time reviewing applications during this same period – an increase of about 32 percent – the average total time for the agency to reach a decision has decreased, reflecting a more robust and efficient program. These metrics reflect not only the strengthening of the medical device review program, but also the dedication of the talented CDRH career staff in carrying out our public health mission and continuing to drive forward critical program enhancements.

We recognize that our approach as regulators must continue to evolve, to anticipate and meet the challenges and opportunities of the coming decades. We must look ahead. We not only have to skate to where the puck will be, we also need to drive the puck to where it should be.

Even by taking these proactive, forward-looking actions, there will be devices that appropriately come to market that we will learn — with further use and experience — pose a new risk or a greater frequency of a known risk. CDRH has made significant strides towards enhancing our nation’s post-market surveillance systems to be able include active surveillance capabilities.

Last week, we described the progress that has been made to build and launch the National Evaluation System for health Technology (or NEST) and the plans that are underway to focus specifically on active surveillance as well as on women’s health devices by strengthening and leveraging the Women’s Health Technologies Coordinated Registry Network. We announced new resources to support these efforts. Based on these and other steps to link different real world sources of information to actively generate data about real world device performance, we’re committing to a new strategic goal: Ensuring that the FDA is consistently first among the world’s regulatory agencies to identify and act upon safety signals related to medical devices.

In the past several years, CDRH has also worked actively to eliminate the use of 510(k)-cleared predicates when the devices raised safety concerns that warranted treating them as high-risk technologies. These efforts will continue. Through a process known as “up-classifying” – meaning that we are re-assigning a device to Class III and requiring premarket approval, our most stringent review pathway, before a device can remain on the market – we can and have made ineligible the use of certain devices as legal predicates. Specific examples include the upclassification of previously cleared 510(k)s for vaginal mesh for the treatment of pelvic organ prolapse, automated external defibrillators, and metal-on-metal hip implants. These devices are higher risk and can no longer be brought to market via the 510(k) pathway.

In fact, since Congress enacted the Medical Device Amendments in 1976, the FDA has made the use of 1,758 devices ineligible as predicates in the 510(k) process. Of these, 1,477 (84 percent) have been upclassified since 2012, reflecting our recent and more aggressive approach to using this authority as the underlying technology of products improves and we develop new information about the safety of existing products. The opportunities offered by more modern innovation can often improve product safety. Most device types we’ve reclassified into class III are older technologies that did not reflect modern standards of safety and effectiveness.

But the regulatory process of up-classifying devices is time- and resource-intensive, and not a good fit for swift action in response to safety concerns. Other tools at our disposal may also be inefficient. For instance, the FDA may determine a need to impose new special controls on a type of 510(k) device, such as new labeling or restrictions on its sale, in response to safety concerns. But this process, which involves rule-making on a case-by-case basis, is lengthy and inefficient, making it challenging to implement necessary safety mitigations in a timely way.

In these situations, we often engage with the manufacturers intensively to encourage them to take the necessary voluntary actions to mitigate a risk. While that approach is generally effective, that solution can be inefficient. And some manufacturers may refuse to cooperate.

In addition, some safety concerns are “cross-cutting” and impact numerous device types. For instance, we’ve seen inadequate reprocessing of reusable devices, such as certain scopes, which can lead to device contamination and patient infections. Misconnections for several device types, such as small-bore connectors, has resulted in death, serious injuries and device malfunctions. While the FDA has taken appropriate action in these cases, they demonstrate how the current regulatory process for implementing special controls to enhance device safety is simply not agile enough to address time-sensitive public health issues.

Thus, we believe that additional changes are needed to fully modernize the 510(k) program.

After careful review of our ability to impose special controls to better protect patients, we believe that more streamlined processes would improve FDA’s ability to implement new special controls to address safety concerns more quickly, as well as to up-classify a device type, where appropriate, in response to a safety concern. These refinements to FDA’s approach would complement our work on NEST by allowing us to more rapidly require appropriate mitigations in response to an identified safety issue. We look forward to continuing to engage with Congress and stakeholders about potential proposals to address these patient safety needs.

As a result of our 510(k) policy proposals, we also believe that more devices will use the De Novo pathway, which permits a robust evaluation of novel devices and allows the FDA to establish special controls for devices of the same type. In the next few weeks, we plan to issue a proposed rule clarifying procedures and requirements for submissions of De Novo requests, further advancing our efforts to establish a regulatory framework that sets clear standards, expectations and processes for De Novo classification as a way to continue to modernize the 510(k) process.

We know that some of these proposals may require additional support from Congress. But we believe that these are the right steps to advance safety and innovation, and we’re committed to these ideas and committed to working with stakeholders to continue to modernize our policies.

The technological advances in medical devices and their ability to improve the lives of patients are creating tremendous public health promise. But as physicians, we also understand the real harm that devices may cause if they malfunction, are misused, or are made of poor quality.

The continued integrity of the 510(k) program, as a means to assure the safety and effectiveness of devices, is a top priority for us, and for the FDA. Part of our commitment to protect patients is to recognize that all devices pose benefits and risks, and to seek ways to minimize those risks.

We’re seizing the chance to make a generational change in the framework for 510(k) reviews – one that advances its best features while making sure it keeps pace with modern innovation.

In the coming weeks, we’ll provide additional updates on the status of our Medical Device Safety Action Plan and describe further steps we’re taking to promote patient safety. We’re proud of the work CDRH staff is doing to make sure that the devices we regulate are safe. We’ll continue to take new actions to strengthen the device program for the years to come.

###

SOURCE: FDA Statement, Nov 26, 2018 – https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm626572.htm

With 13 years of marketing and eCommerce experience, he brings a wealth of digital knowledge and expertise to the business.

Tom joined in 2018, leading the launch of Ortho Consulting Groups brand, marketing strategy, conference planning and the ongoing development of the Ortho Consulting Groups websites and CRM.

Michel Orsinger Assumes Role as Chairman of LimaCorporate’s Advisory Board

Michel Orsinger Assumes Role as Chairman of LimaCorporate’s Advisory Board

SAN DANIELE DEL FRIULI, Italy, November 19, 2018 /PRNewswire/ —

LimaCorporate is pleased to announce that Michel Orsinger, Board Member of LimaCorporate’s Advisory Board, will assume the role of Chairman of the Board. Michel joined the Advisory Board mid-2017 following a long and successful global career in Orthopaedics.

Michel Orsinger held the position of Worldwide Chairman DePuy Synthes Companies at Johnson & Johnson (“J&J”) from 2012 to 2015, where he was also a member of J&J’s Global Management Team. Michel joined J&J following the sale of Synthes Inc. for $20 billion in 2012. Subsequently, Michel established the worldwide largest and most comprehensive orthopaedic company. Prior to his leadership role at J&J, Michel Orsinger was COO and CEO of Synthes Inc. for eight years and spent 11 years with Novartis.

Today, Michel is an investor as well as board member of several start-up companies, Chairman of a VC Fund and a senior advisor to EQT. He also joined the Board of the pharmaceutical company Takeda in 2016.

Valentin Chapero, who held the Chairman of the Board position from 2016, contributed to focusing the LimaCorporate strategic value proposition in terms of market approach, product portfolio and core technologies. He promoted operational excellence through the alignment of business processes as well as providing direction to expand LimaCorporate in M&A activities. Valentin also influenced the important country reorganizations rendering a customer-focused organization in many of LimaCorporate’s direct markets. Michel will now build on Valentin’s work making use of his global leadership experience, Orthopaedic expertise and extensive industry network.

“Michel Orsinger will bring LimaCorporate to the next level as he has demonstrated in many other companies. He is a quality veteran of our industry with a strong track record of success which will enable him and the Advisory Board to support LimaCorporate’s development, including to push our digital agenda recently accelerated with the milestone-based acquisition of TechMah Medical LLC. I look forward to closely collaborating with Michel and I would like to personally thank Valentin for his dedication and leadership he brought to LimaCorporate”, said Luigi Ferrari, CEO of Lima Corporate.

About LimaCorporate
LimaCorporate is a global medical device company providing reconstructive and custom-made Orthopaedic solutions to surgeons who face the challenges of improving the quality of life of their patients. Based in Italy, LimaCorporate is committed to the development of innovative products and procedures to enable surgeons to select ideal solution for every individual patient. LimaCorporate’s product range includes large joint revision and primary implants and complete extremities solutions including fixation.

For additional information on the Company, please visit: limacorporate.com

SOURCE Limacorporate S.p.A. – PRNewswire, Nov 19, 2018 – Michel Orsinger Assumes Role as Chairman of LimaCorporate’s Advisory Board 

With 13 years of marketing and eCommerce experience, he brings a wealth of digital knowledge and expertise to the business.

Tom joined in 2018, leading the launch of Ortho Consulting Groups brand, marketing strategy, conference planning and the ongoing development of the Ortho Consulting Groups websites and CRM.

EOS imaging to Present Its EOSapps Suite at the French Society of Orthopedic and Traumatological Surgery Congress (SOFCOT)

EOS imaging to Present Its EOSapps Suite at the French Society of Orthopedic and Traumatological Surgery Congress (SOFCOT)

Symposium to showcase Total Hip Arthroplasty (THA) results with EOS analysis

First time association of hipEOS with intra-operative navigation to execute surgical plan

PARIS–(BUSINESS WIRE)–Regulatory News:

EOS imaging  (Paris:EOSI) (Euronext, FR0011191766 – EOSI – Eligible PEA – PME), a pioneer in 2D/3D orthopedic medical imaging, will present its EOSapps solution with particular focus on hipEOS 3.0 online surgical planning software at the French Society of Orthopedic and Traumatological Surgery (SOFCOT) Congress, being held November 12-15, 2018 at the Palais des Congrès in Paris.

The congress program will include the symposium: “Planning, Executing, Evaluating the Total Hip Arthproplasty: EOS Solutions at Each Step of the Care Pathway” on Wednesday, November 14th at 12:30 pm in Room 343, with Professor Jean Yves Lazennec (AP-HP, Paris) and Doctor Nicolas Verdier (Clinique Jean Villar, Bordeaux). Prof. Lazennec address will focus on current progresses in total hip arthroplasty (THA) made possible by post-operative analysis with the EOS solution. Dr. Verdier will share first time results about the association of hipEOS 3D surgical planning with intra-operative navigation (Orthopilot – BBraun) to execute a 3D, personalized plan for patient hip replacement that takes into account the patient anatomy in the weight-bearing and seated functional positions. The anatomical and functional information provided by hipEOS was used in real time in the operating room to guide navigation and achieve optimal positioning of the implant components.

“We are pleased to see presentations at SOFCOT of further progress in hip prosthesis surgery thanks to our 3D imaging and online automated surgical simulation solution. EOS planning, combined with navigation – as well as other per-operative execution systems such as robotics – makes it possible to consider more precise surgeries with better clinical results. We are very proud to be able to offer new perspectives to surgeons and patients to improve the management of THA, a high volume and costly procedure” concluded Marie Meynadier, Chief Executive Officer of EOS imaging.

For more information, stop by EOS Booth # F40 or contact us at: contact@eos-imaging.com

ABOUT EOS IMAGING

EOS imaging is listed on Compartment C of Euronext Paris

ISIN: FR0011191766 – Ticker: EOSI

EOS imaging designs, develops and markets EOS®, a major innovative medical imaging solution dedicated to osteoarticular pathologies and orthopedics combining equipment and services and targeting a $2B per year market opportunity. EOS imaging is currently present in 33 countries, including the United States under FDA agreement, Japan, China and the European Union under CE labelling, through the over 280 installed EOS® platforms representing more than one million patient exams every year. Revenues were €37.1M in 2017, e.g. a +32% CAGR over 2012-2017. For more information, please visit www.eos-imaging.com.

EOS imaging has been selected to integrate the EnterNext © PEA – PME 150 index, composed of 150 French, listed companies on the Euronext markets in Paris.

Contacts

EOS imaging
Marie Meynadier, +33 (0)1 55 25 60 60
CEO
investors@eos-imaging.com
or
Investor Relations (US)
The Ruth Group
Matt Picciano / Emma Poalillo
646-536-7008 / 7024
EOS-imagingIR@theruthgroup.com
or
Press Relations (US)
The Ruth Group
Kirsten Thomas, 508-280-6592
kthomas@theruthgroup.com

SOURCE: BusinessWire, Nov 12, 2018 – https://www.businesswire.com/news/home/20181112005511/en/EOS-imaging-Present-EOSapps-Suite-French-Society

With 13 years of marketing and eCommerce experience, he brings a wealth of digital knowledge and expertise to the business.

Tom joined in 2018, leading the launch of Ortho Consulting Groups brand, marketing strategy, conference planning and the ongoing development of the Ortho Consulting Groups websites and CRM.